Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Tokuyama ( (JP:4043) ) is now available.
Tokuyama Corporation announced its acquisition of JSR Corporation’s in vitro diagnostics and pharmaceutical materials businesses, aiming to enhance its healthcare domain. This strategic move is expected to accelerate product development, generate synergies, and expand market reach in Japan, Korea, and China, positioning Tokuyama as a significant player in the healthcare industry.
More about Tokuyama
Tokuyama Corporation operates in the electronics, healthcare, and environment industries, focusing on products such as in vitro diagnostics and diagnostic pharmaceutical materials. The company aims to expand its healthcare domain and increase its growth business sales to over 60% by 2030.
YTD Price Performance: 9.94%
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.31B
See more data about 4043 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue